Combination therapy with PCSK9 mAbs in post-MI patients
10' education - Sep. 22, 2021 - Derek Connolly, MD, PhD - Birmingham, UK - Online CMEVideo navigation menu
Benefits of LDL-c lowering can happen very early 0:47
How are we doing with regard to LDL-c lowering? 3:17
The ODYSSEY Outcomes and FOURIER trials 3:49
Provide PCSK9 mAbs at the time of MI 7:51
Combination therapy in ACS including PCSK9 mAbs 10:19
What is the anticipated reduction in LDL-c with the combination of statin, ezetimibe and PCSK9i?
- A. 45-50%
- B. 60%
- C. 75%
- D. 85%
- E. 95%
Educational information
This lecture by Derek Connolly was part of an accredited symposium "Redefining intensive LDL-c management in high CV risk patients The case for combination therapy" held during the virtual ESC Congress 2021.
Faculty
Derek Connolly, MD, PhD is a Consultant Interventional Cardiologist and Honorary Senior Clinical Lecturer at Birmingham City Hospital, Birmingham, UK.
Disclosures
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding
Funding for this educational program was provided by unrestricted educational grants received from Amgen, Sanofi, Novartis and Daiichi Sankyo.
Online-CME
This is available as accredited online CME on coursepath for members. Click the button below to enroll:
Enroll
Share this page with your colleagues and friends: